Publisher's Synopsis
The focus of this special issue is a new morpholine antifungal agent, amorolfine, which promises to be a novel therapeutic tool in the treatment of superficial fungal infections. The preclinical, pharmacological and therapeutic aspects of amorolfine are examined by international investigators whose early studies confirm that amorolfine is clinically effective in the treatment of a variety of superficial mycoses. Although there are many effective antifungal agents, the studies on amorolfine indicate that it may be possible to reproduce remissions of fungal nail disease using topical therapy alone as well as to reduce the overall duration of therapy and the frequency of relapse for other varieties of superficial fungal infections.
